Morning Overview on MSN
A 343-patient trial found a new drug combo extended survival in an aggressive brain cancer
People diagnosed with recurrent IDH-mutant grade 3 astrocytoma, a rare and aggressive brain cancer, lived roughly 11 months ...
Huntsman Cancer Institute at the University of Utah (the U) participated in a clinical trial that found that a new combination treatment plan helped people with recurring grade 3 astrocytoma, an ...
A team of researchers from the Nagoya University Graduate School of Medicine has reported that patients with a rare form of brain and spinal cord cancer, localized isocitrate dehydrogenase wild-type ...
Huntsman Cancer Institute at the University of Utah (the U) participated in a clinical trial that found that a new combination treatment plan helped people with recurring grade 3 astrocytoma, an ...
Two years ago, as she was walking into yoga class, Maddy momentarily found herself unable to speak. At first, she thought it was due to anxiety about school, but when it kept happening, and the right ...
Huntsman Cancer Institute at the University of Utah (the U) participated in a clinical trial that found that a new combination treatment plan helped people with recurring grade 3 astrocytoma, an ...
High-grade astrocytoma, which includes glioblastoma, is a fast-growing, aggressive brain cancer that often returns after the tumor is removed, making it difficult to treat. Patients with recurrent ...
The FDA has approved Voranigo to treat certain patients with grade 2 astrocytoma or oligodendroglioma with select mutations, following surgery. The Food and Drug Administration (FDA) has approved ...
A team of researchers from the Nagoya University Graduate School of Medicine has reported that patients with a rare form of brain and spinal cord cancer, localized isocitrate dehydrogenase wild-type ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results